VBWG
Slides

Curriculum Update # 6

• Managing lipids for risk reduction: Focus on the new National Cholesterol Education Program guidelines

This Curriculum Update presents new perspectives on cholesterol management as suggested by the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III or ATP III).

The following areas are covered:

  • New features of ATP III
  • Modifications of lipid and lipoprotein classification
  • Focus on patients with multiple risk factors
  • Secondary prevention: Drug therapy for CHD and CHD-risk equivalents
  • Cholesterol management in patients with acute coronary syndromes
  • The metabolic syndrome as a secondary target of therapy



Published by Medical Education Consultants, Inc. (MEDCON), on behalf of the University of Florida College of Medicine. Supported by an unrestricted educational grant from Pfizer Inc.

©2001 MEDCON

The editorial content of this program expresses the views of the individual contributors and does not necessarily reflect the views or recommendations of the University of Florida College of Medicine, Pfizer Inc, or the publisher. The indications and dosages of drugs discussed in this program may vary from those approved by the Food and Drug Administration (FDA). The reader is advised to consult the full prescribing information for each medication prior to use.


Evolution of NCEP guidelines: ATPI - ATP III

Download CU6.ppt (20 slides - 1.2MB)

Evolution of NCEP guidelines: ATPI - ATP III ATP III: Cholesterol classification (mg/dL) ATP III: High-risk candidates for intensive treatment ATP III: Major risk factors that modify LDL-C goals NCEP/Framingham estimate of 10-year CHD risk in men without  CHD NCEP/Framingham estimate of 10-year CHD risk in women without CHD Framingham point total determines 10-year CHD risk Framingham men: Excess risk of total cholesterol Framingham women: Excess risk of total cholesterol ATP III: Risk categories and LDL-C goals ATP III: LDL-C cutpoints for treatment according to risk category Step care for achieving therapeutic lifestyle changes (TLC) Progression of drug therapy in primary prevention Drug therapy for patients with CHD and CHD risk equivalents Initiating LDL-C-lowering therapy in patients hospitalized with acute coronary events Advantages of aggressive hospital discharge strategy for LDL-C ATP III: Diagnosing the metabolic syndrome ATP III: Considerations in specific age groups Focus on elevated triglycerides (>150 mg/dL) ATP III: Steps to lipid management—Diagnosis and treatment

AdultATPcholesterolCurriculumEducationEvaluationLipidsNCEPPanelperspectivespresents

Related at vwbg.org

Core Curriculum

Insulin Resistance and Cardiovascular Disease: New Perspectives From Vascular Biology

View/Download individual slides (94 Slides)

Vascular Biology in Clinical Practice © Vol. 5, No. 2

Managing lipids in patients with diabetes: New evidence from vascular biology and clinical trials

This monograph, Managing lipids in patients with diabetes: New evidence from vascular biology and clinical trials , is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine.

Vascular Biology in Clinical Practice © Vol. 5, No. 1

New strategies for global risk reduction: Focus on lipids and blood pressure

This monograph, New strategies for global risk reduction: Focus on lipids and blood pressure, is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine.
More related